CCM2 anticorps (N-Term)

N° du produit ABIN616006

Détail du produit anti-CCM2 anticorps

Antigène: CCM2 (Cerebral Cavernous Malformation 2 (CCM2))

Épitope: AA 1-444, N-Term

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp CCM2 est non-conjugé

Application: Western Blotting (WB), Immunofluorescence (IF)

Specificité: This antibody detects recombinant Human CCM-2 in Western Blot and native CCM-2 in Immunohistochemistry.

Réactivité croisée (Details): Species reactivity (tested):Human.

Purification: Protein A Chromatography

Immunogène: Highly pure (> 95%) recombinant Human CCM-2 (Cerebral cavernous malformations 2 protein, aa: Met1-Ala444) from E.coli.

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Reconstitution: Restore in sterile water to a concentration of 0.1-1.0 mg/mL.

Buffer: 5 mM PBS pH 7.2 without preservatives

Agent conservateur: Without preservative

Conseil sur la manipulation: Avoid repeated freezing and thawing.

Stock: 4 °C/-20 °C

Stockage commentaire: Prior to reconstitution store at 2-8 °C for one month or dessicated at -20 °C for longer. Following reconstitution store undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

Détails sur CCM2

Antigène: CCM2 (Cerebral Cavernous Malformation 2 (CCM2))

Autre désignation: Malcavernin (CCM2 Produits)

Synonymes: anticorps C7orf22, anticorps OSM, anticorps malcavernin, anticorps CCM2, anticorps BC029157, anticorps TUF2, anticorps vtn, anticorps zgc:110233, anticorps CCM2 scaffolding protein, anticorps cerebral cavernous malformation 2, anticorps malcavernin, anticorps CCM2, anticorps Ccm2, anticorps LOC100304744, anticorps ccm2

Sujet: Cerebral cavernous malformations (CCMs) are sporadically acquired or inherited vascular lesions of the central nervous system consisting of clusters of dilated thin-walled blood vessels that predispose individuals to seizures and stroke. Familial CCM is caused by mutations in KRIT1 (CCM1) or in malcavernin (CCM2). The roles of the CCM proteins in the pathogenesis of the disorder remain largely unknown. It was shown that the CCM1 gene product, KRIT1, interacts with the CCM2 gene product, malcavernin. Analogous to the established interactions of CCM1 and beta1 integrin with ICAP1, the CCM1/CCM2 association is dependent upon the phosphotyrosine binding (PTB) domain of CCM2. A familial CCM2 missense mutation abrogates the CCM1/CCM2 interaction, suggesting that loss of this interaction may be critical in CCM pathogenesis. CCM2 and ICAP1 bound to CCM1 via their respective PTB domains differentially influence the subcellular localization of CCM1. The data indicate that the genetic heterogeneity observed in familial CCM may reflect mutation of different molecular members of a coordinated signaling complex.Synonyms: C7orf22, CCM2, Cerebral cavernous malformations 2 protein, PP10187

ID gène: 83605

NCBI Accession: NP_001025006

UniProt: Q9BSQ5

Pathways: Cell-Cell Junction Organization